Logo.PNG
HilleVax Announces Executive Management Appointments and Promotions
January 09, 2023 07:00 ET | HilleVax, Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
Logo.PNG
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 16:05 ET | HilleVax, Inc.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
December 05, 2022 06:30 ET | HilleVax, Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results...
Logo.PNG
HilleVax to Participate in November Investor Conferences
November 10, 2022 18:30 ET | HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 10, 2022 16:05 ET | HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Logo.PNG
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
September 01, 2022 17:18 ET | HilleVax, Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
August 31, 2022 07:00 ET | HilleVax, Inc.
Enrollment of remaining subjects in NEST-IN1 has resumed Immunogenicity results from the first 200 subjects expected in Q4 2022 BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc....
Logo.PNG
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
August 15, 2022 07:00 ET | HilleVax, Inc.
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 10, 2022 16:01 ET | HilleVax, Inc.
BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Logo.PNG
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
July 20, 2022 16:05 ET | HilleVax, Inc.
Pan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214 BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a...